Effect of advanced glycosylation end products (AGEs) on proliferation of human bone marrow mesenchymal stem cells (MSCs) in vitro

In Vitro Cellular and Developmental Biology - Animal

Volumn 48, Issue 9, 2012, Pages 599-602

  Lu, Yi Qun ^a   Lu, Yan ^a   Li, Hui Juan ^a   Cheng, Xing Bo ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Advanced glycosylation end products; Bone marrow mesenchymal stem cells; Cell proliferation; Oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT;

ARTICLE; CELL CULTURE; CELL PROLIFERATION; CULTURE MEDIUM; CULTURE TECHNIQUE; CYTOLOGY; DRUG EFFECT; HOMEOSTASIS; HUMAN; MESENCHYMAL STROMA CELL; OXIDATIVE STRESS; TUMOR MICROENVIRONMENT;

CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELLS, CULTURED; CELLULAR MICROENVIRONMENT; CULTURE MEDIA; GLYCOSYLATION END PRODUCTS, ADVANCED; HOMEOSTASIS; HUMANS; MESENCHYMAL STROMAL CELLS; OXIDATIVE STRESS;

BOVINAE;

EID: 84872018203     PISSN: 10712690     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11626-012-9551-7     Document Type: Article

References (22)

1. Aziz M. T.; El-Asmar M. F.; Haidara M.; Atta H. M.; Roshdy N. K.; Rashed L. A.; Sabry D.; Youssef M. A.; Aziz A. T. A.; Moustafa M. Effect of bone marrow-derived mesenchymal stem cells on cardiovascular complications in diabetic rats. Med. Sci. Monit. 14: 255; 2008.
2. Chen J.; Song M.; Yu S.; Gao P.; Yu Y.; Wang H.; Huang L. Advanced glycation endproducts alter functions and promote apoptosis in endothelial progenitor cells through receptor for advanced glycation endproducts mediate overpression of cell oxidant stress. Mol. Cell. Biochem. 335: 137-146; 2010.
3. Dimmeler S.; Burchfield J.; Zeiher A. M. Cell-based therapy of myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 28: 208-216; 2008.
4. Figliuzzi M.; Cornolti R.; Perico N.; Rota C.; Morigi M.; Remuzzi G.; Remuzzi A.; Benigni A. Bone marrow-derived mesenchymal stem cells improve islet graft function in diabetic rats. Transplant. Proc. 41: 1797-1800; 2009.
5. Goh S. Y.; Cooper M. E. The role of advanced glycation end products in progression and complications of diabetes. J. Clin. Endocrinol. Metab. 93: 1143; 2008.
6. Huijberts M. S.; Schaper N. C.; Schalkwijk C. G. Advanced glycation end products and diabetic foot disease. Diabetes. Metab. Res. Rev. 24(Suppl 1): S19-S24; 2008.
7. Jarajapu Y. P. R.; Grant M. B. The promise of cell-based therapies for diabetic complications. Circ. Res. 106: 854-869; 2010.
8. Kume S.; Kato S.; Yamagishi S.; Inagaki Y.; Ueda S.; Arima N.; Okawa T.; Kojiro M.; Nagata K. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J. Bone Miner. Res. 20: 1647-1658; 2005.
9. Liu Z. J.; Zhuge Y.; Velazquez O. C. Trafficking and differentiation of mesenchymal stem cells. J. Cell. Biochem. 106: 984-991; 2009.
10. Ozdemir A. M.; Hopfer U.; Rosca M. V.; Fan X. J.; Monnier V. M.; Weiss M. F. Effects of advanced glycation end product modification on proximal tubule epithelial cell processing of albumin. Am. J. Nephrol. 28: 14-24; 2008.
11. Quevedo H. C.; Hatzistergos K. E.; Oskouei B. N.; Feigenbaum G. S.; Rodriguez J. E.; Valdes D.; Pattany P. M.; Zambrano J. P.; Hu Q.; McNiece I.; Heldman A. W.; Hare J. M. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc. Natl. Acad. Sci. U. S. A. 106: 14022-14027; 2009.
12. Schmitt A.; Bigl K.; Meiners I.; Schmitt J. Induction of reactive oxygen species and cell survival in the presence of advanced glycation end products and similar structures. BBA -Mol. Basis Dis. 1763: 927-936; 2006.
13. Singh R.; Barden A.; Mori T.; Beilin L. Advanced glycation endproducts: a review. Diabetologia 44: 129-146; 2001.
14. Song G.; Ju Y.; Shen X.; Luo Q.; Shi Y.; Qin J. Mechanical stretch promotes proliferation of rat bone marrow mesenchymal stem cells. Colloids Surf. B. 58: 271-277; 2007.
15. Stolzing A.; Sellers D.; Llewelyn O.; Scutt A. Diabetes induced changes in rat mesenchymal stem cells. Cells Tissues Organs 191: 453-465; 2010.
16. Sun C.; Liang C.; Ren Y.; Zhen Y.; He Z.; Wang H.; Tan H.; Pan X.; Wu Z. Advanced glycation end products depress function of endothelial progenitor cells via p38 and ERK 1/2 mitogenactivated protein kinase pathways. Basic Res. Cardiol. 104: 42-49; 2009a.
17. Sun L.; Akiyama K.; Zhang H.; Yamaza T.; Hou Y.; Zhao S.; Xu T.; Le A.; Shi S. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 27: 1421-1432; 2009b.
18. Urban V. S.; Kiss J.; Kovacs J.; Gocza E.; Vas V.; Monostori E.; Uher F. Mesenchymal stem cells cooperate with bone marrow cells in therapy of diabetes. Stem Cells 26: 244-253; 2008.
19. Vija L.; Farge D.; Gautier J. F.; Vexiau P.; Dumitrache C.; Bourgarit A.; Verrecchia F.; Larghero J. Mesenchymal stem cells: stem cell therapy perspectives for type 1 diabetes. Diabetes Metab. 35: 85-93; 2009.
20. Yamagishi S.; Matsui T.; Nakamura K.; Inoue H.; Takeuchi M.; Ueda S.; Fukami K.; Okuda S.; Imaizumi T. Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. Microvasc. Res. 75: 130-134; 2008.
21. Yan S. D.; Schmidt A. M.; Anderson G. M.; Zhang J.; Brett J.; Zou Y. S.; Pinsky D.; Stern D. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/ binding proteins. J. Biol. Chem. 269: 9889-9897; 1994.
22. Yang K.; Wang X. Q.; He Y. S.; Lu L.; Chen Q. J.; Liu J.; Shen W. F. Advanced glycation end products induce chemokine/cytokine production via activation of p38 pathway and inhibit proliferation and migration of bone marrow mesenchymal stem cells. Cardiovasc. Diabetol. 9: 66; 2010.